Portal To Collate Data On Spurious Drugs In Works

New Delhi : India’s drug regulatory organization is planning to launch a unified portal to develop a digital drugs regulatory system. The system will maintain a database of drugs that are not standard quality or are spurious to build trust in their quality across domestic and global markets.

A unified portal which will maintain a database of drugs that are not of standard quality or are spurious is in the offing.

With an aim to build trust on the quality of drugs in the domestic and global markets, India’s drug regulatory organisation is all set to introduce a new unified portal for developing a digital drugs regulatory system (DRS).

The drug regulator has asked for suggestions from various government agencies over the proposed portal including all state drug controllers, customs, ministry of environment, drug manufacturing associations, Indian Council of Medical research, Bureau ofIndian Standards (BIS), among others.

Related Posts

  • Pharma
  • June 19, 2025
  • 100 views
Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

This small-cap pharma stock, engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets, rose over 2% in today’s trade after receiving approval for its product…

  • Pharma
  • June 19, 2025
  • 126 views
HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

ED raids three pharma units in Baddi, Nalagarh

ED raids three pharma units in Baddi, Nalagarh

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations